| Abstrakt: |
A recent study conducted in Boston, Massachusetts, explores the current understanding and clinical management of gastroesophageal adenocarcinomas (GEAs), which include esophageal, gastroesophageal junction, and gastric adenocarcinomas. The research highlights the importance of biomarker-directed approaches and immune checkpoint inhibitors (ICIs) in the treatment of GEA. Specifically, the study emphasizes the significance of mismatch repair deficiency and/or high microsatellite instability (dMMR/MSI-H) in a subset of GEA patients, as these tumors are associated with a more favorable prognosis and significant benefit from ICIs. The authors recommend MMR/MSI testing for all GEA patients and discuss the implications for clinical management across disease stages. [Extracted from the article] |
